nach oben

Current Pulmonology Reports

Erschienen in:

26.11.2019 | Bronchiectasis (A Schmid, Section Editor)

Nontuberculous Mycobacteria Infection: Source and Treatment

verfasst von: Justin M. Hutchison, Ya Zhang, Stephen Waller

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review offers current understanding of the source of nontuberculous mycobacteria (NTM) infections especially in relation to engineered water systems. It provides a summary of current treatment methods and highlights novel treatment options being developed.

Recent Findings

Nontuberculous mycobacteria (NTM) infections are thought to originate from inhalation or aspiration of NTM from contaminated drinking water. While significant NTM metagenomics analysis and culturing of environmental samples have been performed, the bias of culture independent and dependent techniques along with the ubiquity of NTM organisms in the environment has made connecting the pathogen reservoir and route of transmission difficult. Recent advances in NTM DNA extraction protocols and NTM high-throughput sequencing methods suggest inhalation and aspiration of drinking water remain a critical route of transmission.

Summary

The development of pulmonary diseases associated with NTM infections is complex. Patients with CF and non-CF bronchiectasis are susceptible to NTM infections, whereas the development of bronchiectasis may be due to long-term exposure to NTM. Source attribution of NTM infections is critical, especially if the source includes engineered water systems such as drinking water distribution networks and clinical and non-clinical premise plumbing. However, source identification requires more work. Current NTM treatment therapies were developed for other indications. New and combined therapies are being developed, but are insufficient to address growing antibiotic resistance and diversity of NTM infections.

Strollo SE, Adjemian J, Adjemian MK, Prevots DR. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc. 2015;12(10):1458–64. https://doi.org/10.1513/AnnalsATS.201503-173OC.CrossRefPubMedPubMedCentral

Donohue MJ, Wymer L. Increasing prevalence rate of nontuberculous mycobacteria infections in five states, 2008–2013. Ann Am Thorac Soc. 2016;13(12):2143–50. https://doi.org/10.1513/AnnalsATS.201605-353OC.CrossRefPubMed

Jones MM, Winthrop KL, Nelson SD, Duvall SL, Patterson OV, Nechodom KE, et al. Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration. PLoS One. 2018;13(6):e0197976. https://doi.org/10.1371/journal.pone.0197976.CrossRefPubMedPubMedCentral

Collier SA, Stockman LJ, Hicks LA, Garrison LE, Zhou FJ, Beach MJ. Direct healthcare costs of selected diseases primarily or partially transmitted by water. Epidemiol Infect. 2012;140(11):2003–13. https://doi.org/10.1017/S0950268811002858.CrossRefPubMedPubMedCentral

• Dowdell K, Haig SJ, Caverly LJ, Shen Y, LiPuma JJ, Raskin L. Nontuberculous mycobacteria in drinking water systems - the challenges of characterization and risk mitigation. Curr Opin Biotechnol. 2019;57:127–36. https://doi.org/10.1016/j.copbio.2019.03.010Dowdell et al. highlight the difficulty of identifying pathogenic NTM in drinking water supplies. This review summarizes additional hurdles required to connect the organisms responsible for patient infection with the source of the infection.CrossRefPubMed

Kim SY, Shin SH, Moon SM, Yang B, Kim H, Kwon OJ, et al. Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens. Diagn Microbiol Infect Dis. 2017;88(2):125–37. https://doi.org/10.1016/j.diagmicrobio.2017.02.017.CrossRefPubMed

Farnia P, Farnia P, Ghanavi J, Velayati AA. Epidemiological distribution of nontuberculous mycobacteria using geographical information system. Nontuberculous Mycobacteria (NTM). Elsevier. 2019:191–321.

Yano H, Iwamoto T, Nishiuchi Y, Nakajima C, Starkova DA, Mokrousov I, et al. Population structure and local adaptation of MAC lung disease agent Mycobacterium avium subsp. hominissuis. Genome Biol Evol. 2017;9(9):2403–17. https://doi.org/10.1093/gbe/evx183.CrossRefPubMedPubMedCentral

Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis. 2015;21(9):1638–46. https://doi.org/10.3201/2109.141634.CrossRefPubMedPubMedCentral

10.

Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect. 2009;15(10):906–10. https://doi.org/10.1111/j.1469-0691.2009.03014.x.CrossRefPubMed

11.

Gonzalez-Santiago TM, Drage LA. Nontuberculous mycobacteria: skin and soft tissue infections. Dermatol Clin. 2015;33(3):563–77. https://doi.org/10.1016/j.det.2015.03.017.CrossRefPubMed

12.

Loizos A, Soteriades ES, Pieridou D, Koliou MG. Lymphadenitis by non-tuberculous mycobacteria in children. Pediatr Int. 2018;60(12):1062–7. https://doi.org/10.1111/ped.13708.CrossRefPubMed

13.

Haverkamp MH, Arend SM, Lindeboom JA, Hartwig NG, van Dissel JT. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis. 2004;39(4):450–6. https://doi.org/10.1086/422319.CrossRefPubMed

14.

Tebruegge M, Pantazidou A, MacGregor D, Gonis G, Leslie D, Sedda L, et al. Nontuberculous mycobacterial disease in children - epidemiology, diagnosis & management at a tertiary center. PLoS One. 2016;11(1):e0147513. https://doi.org/10.1371/journal.pone.0147513.CrossRefPubMedPubMedCentral

15.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous Mycobacterium. Science. 2016;354(6313):751–7. https://doi.org/10.1126/science.aaf8156.CrossRefPubMedPubMedCentral

16.

• Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration. 2016;91(5):386–402. https://doi.org/10.1159/000445906Wassilew et al. provide an excellent review on the epidemiology of NTM pulmonary disease, review of known risk factors for mycobacterial infection, and provide a thorough and comprehensive review of treatment recommendations for common NTM clinical scenarios.CrossRefPubMed

17.

Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13. https://doi.org/10.1183/09031936.00149212.CrossRefPubMed

18.

Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, et al. Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives. Expert Rev Respir Med. 2017;11(12):977–89. https://doi.org/10.1080/17476348.2017.1386563.CrossRefPubMed

19.

Nishiuchi Y, Iwamoto T, Maruyama F. Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium complex. Front Med (Lausanne). 2017;4(27):27. https://doi.org/10.3389/fmed.2017.00027.CrossRefPubMedPubMedCentral

20.

Donohue MJ, King D, Pfaller S, Mistry JH. The sporadic nature of Legionella pneumophila, Legionella pneumophila Sg1 and Mycobacterium avium occurrence within residences and office buildings across 36 states in the United States. J Appl Microbiol. 2019;126(5):1568–79. https://doi.org/10.1111/jam.14196.CrossRefPubMedPubMedCentral

21.

Loret JF, Dumoutier N. Non-tuberculous mycobacteria in drinking water systems: a review of prevalence data and control means. Int J Hyg Environ Health. 2019;222(4):628–34. https://doi.org/10.1016/j.ijheh.2019.01.002.CrossRefPubMed

22.

Donohue MJ, Mistry JH, Donohue JM, O’Connell K, King D, Byran J, et al. Increased frequency of nontuberculous mycobacteria detection at potable water taps within the United States. Environ Sci Technol. 2015;49(10):6127–33. https://doi.org/10.1021/acs.est.5b00496.CrossRefPubMed

23.

Gomez-Smith CK, LaPara TM, Hozalski RM. Sulfate reducing bacteria and mycobacteria dominate the biofilm communities in a chloraminated drinking water distribution system. Environ Sci Technol. 2015;49(14):8432–40. https://doi.org/10.1021/acs.est.5b00555.CrossRefPubMed

24.

Wallace RJ Jr, Iakhiaeva E, Williams MD, Brown-Elliott BA, Vasireddy S, Vasireddy R, et al. Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease. J Clin Microbiol. 2013;51(6):1747–52. https://doi.org/10.1128/JCM.00186-13.CrossRefPubMedPubMedCentral

25.

Vaerewijck MJ, Huys G, Palomino JC, Swings J, Portaels F. Mycobacteria in drinking water distribution systems: ecology and significance for human health. FEMS Microbiol Rev. 2005;29(5):911–34. https://doi.org/10.1016/j.femsre.2005.02.001.CrossRefPubMed

26.

Honda JR, Hasan NA, Davidson RM, Williams MD, Epperson LE, Reynolds PR, et al. Environmental nontuberculous mycobacteria in the Hawaiian Islands. PLoS Negl Trop Dis. 2016;10(10):e0005068. https://doi.org/10.1371/journal.pntd.0005068.CrossRefPubMedPubMedCentral

27.

Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011;17(3):419–24. https://doi.org/10.3201/eid1703.101510.CrossRefPubMedPubMedCentral

28.

Thomson R, Tolson C, Carter R, Coulter C, Huygens F, Hargreaves M. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol. 2013;51(9):3006–11. https://doi.org/10.1128/JCM.00899-13.CrossRefPubMedPubMedCentral

29.

Hamilton LA, Falkinham JO. 3rd. Aerosolization of Mycobacterium avium and Mycobacterium abscessus from a household ultrasonic humidifier. J Med Microbiol. 2018;67(10):1491–5. https://doi.org/10.1099/jmm.0.000822.CrossRefPubMed

30.

Mullis SN, Falkinham JO 3rd. Adherence and biofilm formation of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materials. J Appl Microbiol. 2013;115(3):908–14. https://doi.org/10.1111/jam.12272.CrossRefPubMed

31.

Falkinham JO 3rd. Mycobacterium avium complex: adherence as a way of life. AIMS Microbiol. 2018;4(3):428–38. https://doi.org/10.3934/microbiol.2018.3.428.CrossRefPubMedPubMedCentral

32.

Greub G, Raoult D. Microorganisms resistant to free-living amoebae. Clin Microbiol Rev. 2004;17(2):413–33. https://doi.org/10.1128/cmr.17.2.413-433.2004.CrossRefPubMedPubMedCentral

33.

Kotlarz N, Rockey N, Olson TM, Haig SJ, Sanford L, LiPuma JJ, et al. Biofilms in full-scale drinking water ozone contactors contribute viable bacteria to ozonated water. Environ Sci Technol. 2018;52(5):2618–28. https://doi.org/10.1021/acs.est.7b04212.CrossRefPubMed

34.

Taylor RH, Falkinham JO 3rd, Norton CD, LeChevallier MW. Chlorine, chloramine, chlorine dioxide, and ozone susceptibility of Mycobacterium avium. Appl Environ Microbiol. 2000;66(4):1702–5. https://doi.org/10.1128/aem.66.4.1702-1705.2000.CrossRefPubMedPubMedCentral

35.

Wang J, Sui M, Yuan B, Li H, Lu H. Inactivation of two mycobacteria by free chlorine: effectiveness, influencing factors, and mechanisms. Sci Total Environ. 2019;648:271–84. https://doi.org/10.1016/j.scitotenv.2018.07.451.CrossRefPubMed

36.

Norton CD, LeChevallier MW, Falkinham JO 3rd. Survival of Mycobacterium avium in a model distribution system. Water Res. 2004;38(6):1457–66. https://doi.org/10.1016/j.watres.2003.07.008.CrossRefPubMed

37.

Lewis AH, Falkinham JO 3rd. Microaerobic growth and anaerobic survival of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium scrofulaceum. Int J Mycobacteriol. 2015;4(1):25–30. https://doi.org/10.1016/j.ijmyco.2014.11.066.CrossRefPubMed

38.

Cirillo JD, Falkow S, Tompkins LS, Bermudez LE. Interaction of Mycobacterium avium with environmental amoebae enhances virulence. Infect Immun. 1997;65(9):3759–67.PubMedPubMedCentral

39.

Norton GJ, Virdi R, Epperson E, Hasan NA, Bai X, Strong M, et al. Mycobacterium avium hominissuis virulence and genomic adaptations after long-term co-culture in Acanthamoeba. NTM: Am J Resp Crit Care Med. 2019:A2045-A.

40.

Schiavano GF, De Santi M, Sisti M, Amagliani G, Brandi G. Disinfection of Mycobacterium avium subspecies hominissuis in drinking tap water using ultraviolet germicidal irradiation. Environ Technol. 2018;39(24):3221–7. https://doi.org/10.1080/09593330.2017.1375028.CrossRefPubMed

41.

Perrott P, Turgeon N, Gauthier-Levesque L, Duchaine C. Preferential aerosolization of bacteria in bioaerosols generated in vitro. J Appl Microbiol. 2017;123(3):688–97. https://doi.org/10.1111/jam.13514.CrossRefPubMed

42.

Gauthier-Levesque L, Bonifait L, Turgeon N, Veillette M, Perrott P, Grenier D, et al. Impact of serotype and sequence type on the preferential aerosolization of Streptococcus suis. BMC Res Notes. 2016;9:273. https://doi.org/10.1186/s13104-016-2073-8.CrossRefPubMedPubMedCentral

43.

Mathieu L, Bertrand I, Abe Y, Angel E, Block JC, Skali-Lami S, et al. Drinking water biofilm cohesiveness changes under chlorination or hydrodynamic stress. Water Res. 2014;55:175–84. https://doi.org/10.1016/j.watres.2014.01.054.CrossRefPubMed

44.

Schwake DO, Garner E, Strom OR, Pruden A, Edwards MA. Legionella DNA markers in tap water coincident with a spike in Legionnaires’ disease in Flint, MI. Environ Sci Technol Lett. 2016;3(9):311–5. https://doi.org/10.1021/acs.estlett.6b00192.CrossRef

45.

Shukla MA, Woc-Colburn L, Weatherhead JE. Infectious diseases in the aftermath of hurricanes in the United States. Curr Trop Med Reports. 2018;5(4):217–23. https://doi.org/10.1007/s40475-018-0162-6.CrossRef

46.

• Haig SJ, Kotlarz N, JJ LP, Raskin L. A high-throughput approach for identification of nontuberculous mycobacteria in drinking water reveals relationship between water age and Mycobacterium avium. MBio. 2018;9(1):e02354–17. https://doi.org/10.1128/mBio.02354-17Highlights new methods for extracting higher quantities of NTM DNA while showing longer water age in distribution systems correlated with higher abundance ofM. aviumsubsp.avium.CrossRefPubMedPubMedCentral

47.

Richards CL, Broadaway SC, Eggers MJ, Doyle J, Pyle BH, Camper AK, et al. Detection of pathogenic and non-pathogenic bacteria in drinking water and associated biofilms on the Crow Reservation, Montana. USA. Microb Ecol. 2018;76(1):52–63. https://doi.org/10.1007/s00248-015-0595-6.CrossRefPubMed

48.

Li T, Abebe LS, Cronk R, Bartram J. A systematic review of waterborne infections from nontuberculous mycobacteria in health care facility water systems. Int J Hyg Environ Health. 2017;220(3):611–20. https://doi.org/10.1016/j.ijheh.2016.12.002.CrossRefPubMed

49.

Hull NM, Holinger EP, Ross KA, Robertson CE, Harris JK, Stevens MJ, et al. Longitudinal and source-to-tap New Orleans, LA, U.S.A. drinking water microbiology. Environ Sci Technol. 2017;51(8):4220–9. https://doi.org/10.1021/acs.est.6b06064.CrossRefPubMed

50.

Casini B, Buzzigoli A, Cristina ML, Spagnolo AM, Del Giudice P, Brusaferro S, et al. Long-term effects of hospital water network disinfection on Legionella and other waterborne bacteria in an Italian university hospital. Infect Control Hosp Epidemiol. 2014;35(3):293–9. https://doi.org/10.1086/675280.CrossRefPubMed

51.

Perkins KM, Reddy SC, Fagan R, Arduino MJ, Perz JF. Investigation of healthcare infection risks from water-related organisms: summary of CDC consultations, 2014-2017. Infect Control Hosp Epidemiol. 2019;40(6):621–6. https://doi.org/10.1017/ice.2019.60.CrossRefPubMed

52.

Kanamori H, Weber DJ, Rutala WA. Healthcare outbreaks associated with a water reservoir and infection prevention strategies. Clin Infect Dis. 2016;62(11):1423–35. https://doi.org/10.1093/cid/ciw122.CrossRefPubMed

53.

Shakoor S, Owais M, Hasan R, Irfan S. Nosocomial and healthcare-associated NTM infections and their control. Nontuberculous Mycobacteria (NTM). Elsevier. 2019:177–90.

54.

Ninh A, Weiner M, Goldberg A. Healthcare-associated Mycobacterium chimaera infection subsequent to heater-cooler device exposure during cardiac surgery. J Cardiothorac Vasc Anesth. 2017;31(5):1831–5. https://doi.org/10.1053/j.jvca.2017.05.028.CrossRefPubMed

55.

Sebakova H, Kozisek F, Mudra R, Kaustova J, Fiedorova M, Hanslikova D, et al. Incidence of nontuberculous mycobacteria in four hot water systems using various types of disinfection. Can J Microbiol. 2008;54(11):891–8. https://doi.org/10.1139/w08-080.CrossRefPubMed

56.

• Falkinham JO 3rd. Challenges of NTM drug development. Front Microbiol. 2018;9:1613. https://doi.org/10.3389/fmicb.2018.01613Falkinham highlights unique characteristics of NTM organisms that require consideration when developing antimicrobial therapies.CrossRefPubMedPubMedCentral

57.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. https://doi.org/10.1164/rccm.200604-571ST.CrossRefPubMed

58.

Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–ii64. https://doi.org/10.1136/thoraxjnl-2017-210927.CrossRefPubMed

59.

Mahboubi MA, Carmody LA, Foster BK, Kalikin LM, VanDevanter DR, LiPuma JJ. Culture-based and culture-independent bacteriologic analysis of cystic fibrosis respiratory specimens. J Clin Microbiol. 2016;54(3):613–9. https://doi.org/10.1128/JCM.02299-15.CrossRefPubMedPubMedCentral

60.

• Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15(8):968–80. https://doi.org/10.1016/S1473-3099(15)00089-4Wu and Holland offer a nice review of the host defense mechanisms against mycobacterial infections and include information on those with immunodeficiencies, in whom focal and disseminated mycobacterial infections can occur.CrossRef

61.

Chalmers JD. New insights into the epidemiology of bronchiectasis. Chest. 2018;154(6):1272–3. https://doi.org/10.1016/j.chest.2018.08.1051.CrossRefPubMed

62.

Reich JM. Non-TB mycobacterial infection-bronchiectasis nexus. Chest. 2019;155(6):1301–2. https://doi.org/10.1016/j.chest.2019.01.037.CrossRefPubMed

63.

Bonaiti G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S. Nontuberculous mycobacteria in noncystic fibrosis bronchiectasis. Biomed Res Int. 2015;2015:197950. https://doi.org/10.1155/2015/197950.CrossRefPubMedPubMedCentral

64.

King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411–9.CrossRef

65.

Jonsson BE, Bylund J, Johansson BR, Telemo E, Wold AE. Cord-forming mycobacteria induce DNA meshwork formation by human peripheral blood mononuclear cells. Pathog Dis. 2013;67(1):54–66. https://doi.org/10.1111/2049-632X.12007Neutrophils predominate in the defense against extracellular bacteria such as nontuberculous mycobacteria. Organism such asMycobacterium abscessuscan exhibit smooth or rough colony phenotypes. Jönsson et al. review how aggregates of thousands of bacteria, grouped together and surrounded by DNA mesh work, can form a rough phenotype and avoid successful phagocytosis.CrossRefPubMed

66.

Qvist T, Pressler T, Hoiby N, Katzenstein TL. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res. 2014;15(1):41. https://doi.org/10.1186/1465-9921-15-41.CrossRefPubMedPubMedCentral

67.

Esteban J, Garcia-Coca M. Mycobacterium biofilms. Front Microbiol. 2017;8(2651):2651. https://doi.org/10.3389/fmicb.2017.02651.CrossRefPubMed

68.

Johnston JC, Chiang L, Elwood K. Mycobacterium kansasii. Microbiol Spectr. 2017;5(1). https://doi.org/10.1128/microbiolspec.TNMI7-0011-2016.

69.

Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502–19. https://doi.org/10.1016/j.drudis.2018.04.001.CrossRefPubMedPubMedCentral

70.

Griffith DE. Treatment of Mycobacterium avium complex (MAC). Semin Respir Crit Care Med. 2018;39(3):351–61. https://doi.org/10.1055/s-0038-1660472.CrossRefPubMed

71.

Wallace RJ Jr, Zhang Y, Brown-Elliott BA, Yakrus MA, Wilson RW, Mann L, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis. 2002;186(2):266–73. https://doi.org/10.1086/341207.CrossRefPubMed

72.

Kang HK, Park HY, Kim D, Jeong BH, Jeon K, Cho JH, et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis. 2015;15(1):76. https://doi.org/10.1186/s12879-015-0823-1.CrossRefPubMedPubMedCentral

73.

Mitchell JD, Yu JA, Bishop A, Weyant MJ, Pomerantz M. Thoracoscopic lobectomy and segmentectomy for infectious lung disease. Ann Thorac Surg. 2012;93(4):1033–9; discussion 9-40. https://doi.org/10.1016/j.athoracsur.2012.01.012.CrossRefPubMed

74.

Koh WJ, Kim YH, Kwon OJ, Choi YS, Kim K, Shim YM, et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci. 2008;23(3):397–401. https://doi.org/10.3346/jkms.2008.23.3.397.CrossRefPubMedPubMedCentral

75.

Brown-Elliott BA, Rubio A, Wallace RJ Jr. In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2018;62(11):e01503–18. https://doi.org/10.1128/AAC.01503-18.CrossRefPubMedPubMedCentral

76.

Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–59. https://doi.org/10.1128/AAC.45.3.649-659.2001.CrossRefPubMedPubMedCentral

77.

• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–3. https://doi.org/10.1038/s41591-019-0437-zDedrick et al. provide evidence of the effectiveness of NTM phage treatment. Phage treatment halted advancement of a disseminated, antibiotic-resistant MAB infection.CrossRefPubMedPubMedCentral

78.

Faruque SM, Islam MJ, Ahmad QS, Faruque AS, Sack DA, Nair GB, et al. Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. Proc Natl Acad Sci U S A. 2005;102(17):6119–24. https://doi.org/10.1073/pnas.0502069102.CrossRefPubMedPubMedCentral

Titel: Nontuberculous Mycobacteria Infection: Source and Treatment
verfasst von: Justin M. Hutchison
Ya Zhang
Stephen Waller
Publikationsdatum: 26.11.2019
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2019
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-019-00237-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Nontuberculous Mycobacteria Infection: Source and Treatment

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin